1. Introduction {#sec1}
===============

Traumatic brain injury (TBI) is a major cause of death and disability among both civilians and military personnel. In the United States, TBI is sustained by approximately two million people annually and is a major cause of injury-related deaths \[[@r1]-[@r5]\]. Although there are different approaches to classifying TBI, the types of TBI based on the mechanism of injury include closed, penetrating and blast-induced injuries. Closed TBI refers to head trauma resulting from impact or blunt force without any physical compromise to the head layers. Motor vehicle accidents, falls, and sports collisions are some examples of potential causes of closed injury. In penetrating TBI, an object physically penetrates the layers of tissue in the head, thereby causing a wound. The entry of foreign objects, such as low- or high-velocity projectiles from gunshots or fragments resulting from assaults and combat operations (including shrapnel) into the body, is an example of a penetrating injury. Finally, blast- induced TBI results from the explosion of roadside bombs such as improvised explosive devices, to which military personnel in combat-related operations are vulnerable \[[@r6]-[@r12]\].

Specifically, blast-induced TBI has become the signature casualty in the recent military operations in Afghanistan and Iraq and the primary reason for hospitalizations \[[@r13]-[@r18]\]. TBI thus presents a significant social burden and affects a large percentage of the population, including children and young adults \[[@r2], [@r5], [@r19], [@r20]\].

Clinically, the Glasgow Coma Scale (GCS) is used to assess the severity of brain injury. The GCS is a commonly used scoring system to measure neurological impairments and incorporates functions such as eye opening, verbal responses, and motor responses and also serves as a reliable neurological tool for assessing injury-induced loss of consciousness. GCS-based assessments of TBI severity encompass the following classifications: 3-8 for severe injuries, 9-12 for moderate injuries and 13-15 for mild injuries \[[@r21]\]. Statistics indicate that mild TBI accounts for approximately 75% of all reported TBI cases \[[@r22]-[@r26]\]. The diagnostic criteria for mild TBI, as defined by the American Congress of Rehabilitation Medicine, must include one of the following: loss of consciousness not exceeding 30 minutes and a GCS score of 13-15 after the loss of consciousness period; an altered mental state at the time of the accident; or memory loss of the event immediately before or after the accident, with post-traumatic amnesia not exceeding 24 hours \[[@r18], [@r27]\]. The post-concussive symptoms of mild TBI usually include headaches, sleep disturbances, nausea, impaired attention, and memory problems \[[@r28]-[@r32]\].

The pathophysiology associated with TBI is complex, heterogeneous and time-dependent and can be stratified into primary and secondary injury phases. Primary injury refers to the biomechanics of the initial mechanical insult to the head and the resulting effects of the forces on the brain generated by the insult. Depending on the nature of the mechanical insult (*e.g*., blunt impact or blast-induced), the primary injury can be focal or diffuse, *i.e*., localized or distributed throughout the brain parenchyma. Both linear and rotational forces resulting from acceleration/deceleration and twisting/shearing, respectively, can cause mechanical injury in the brain parenchyma \[[@r9], [@r11], [@r33]\]. Primary injury to the brain tissue microstructures, which results from rapid acceleration-deceleration and brain rotation, manifests as damaged axonal cytoskeletal neurofilaments, loss of membrane integrity and axonal injuries \[[@r34]-[@r37]\]. The physics of blast-induced brain injuries are relatively complicated because of the complex blast-wave propagation through the different layers and vascular spaces; the resulting interactions with different regions of the body; and the activation of systemic, local, and cerebral responses \[[@r6], [@r38]-[@r40]\]. Although blast injury is classified into multiple types \[[@r8], [@r40]\], the primary injury discussed in the context of blast in this article, refers to primary blast injury, *i.e*., the exposure of the head to a 'blast' wave itself and the direct effects of blast overpressure on the head and brain tissue layers.

In TBI, the mechanical forces can cause axotomy, which is partial or complete severing of an axon from the neuronal cell body. This action compromises the physical integrity of the intra-axonal structures and transport processes. In the context of severe mechanical injury (*e.g*., rapid acceleration and deceleration insults), axonal severing that is thought to occur at the moment of the initial insult is directly attributed to the mechanical forces and is manifested by axonal disconnection and complete interruption of axonal transport processes. This sparse phenomenon, known as primary axotomy, manifests as single large axonal swelling called the "retraction ball" or terminal "axonal bulb", which are thought to accumulate axonal transport proteins and organelles. Traumatic axonal injury can also cause partial interruption of axonal transport processes along the length of an intact axon, resulting in the formation of periodic axonal swellings called axonal varicosities. In minor forms of trauma, microtubule fragmentation, axonal disconnection and development of degeneration bulbs are attributed to a series of trauma-triggered pathological cascades spanning a large temporal window ranging from hours to days after the initial insult (a process known as secondary or delayed axotomy), although the structural continuity of the axon is conserved at the time of initial insult \[[@r34], [@r35], [@r37], [@r41]-[@r43]\]. Diffuse axonal injury (DAI), a hallmark of mild TBI, is associated with shear-induced damage to the white-matter tracts \[[@r44]-[@r48]\]. Although the primary micro-damage is brief and occurs within milliseconds to seconds, it initiates a slowly evolving cascade of secondary injury mechanisms comprising biophysical, vascular, neurobiological and neuropsychological deficits, as illustrated in [Fig. (**[1](#F1){ref-type="fig"}**)](#F1){ref-type="fig"} \[[@r41], [@r49]-[@r54]\]. The secondary injury cascade spans a broad time scale (from seconds to weeks) and eventually contributes to cell death and function. This complex, multiscale nature of secondary injury pathophysiology makes TBI less amenable to pharmacological treatments.

It is possible that the residual impairment following brain injury could trigger the pathogenesis of several cerebral pathologies \[[@r55]-[@r63]\], and several research groups have provided evidence to support this hypothesis. For example, damage to neuro-axonal structures resulting from brain injuries can trigger the onset of tauopathy, a pathological state in which irreversible phosphorylation of the tau protein causes tau to detach from the axonal site and subsequently migrate from the axon into the soma and toward the dendrites. Consequently, hyper-phosphorylated tau proteins form fibril-like aggregates called neurofibrillary tangles around the dendrites; these tangles then affect neurotransmission, synaptic integration, plasticity and other intra-neuronal/axonal processes \[[@r55], [@r58]-[@r60]\]. Although microglial activation can trigger defense mechanisms (such as neuroinflammation) to conserve physiological homeostasis and promote neuronal repair *via* a variety of molecular mechanisms following injury, uncontrolled and excessive neuroinflammation could act as a driver for chronic neuronal degeneration \[[@r64]-[@r66]\]. It is therefore not surprising that the incidence of post-traumatic neurodegenerative and neuropsychiatric diseases has risen in both civilian and military populations \[[@r7], [@r29], [@r30], [@r67]\]. Furthermore, given the heterogeneity of brain tissue, the diversity of affected neurons and glial cells (as well as their spatial variations across the brain volume) and the selective vulnerability of the neuro-axonal structures to distributed primary blast loads \[[@r61], [@r62], [@r68]-[@r73]\], the propensity of blast-induced TBI to cause comorbid neuropathologies (*e.g*., neuropsychiatric and neurodegenerative, overlapping or sequential) should not be overlooked. Thus, TBI presents a major public health challenge and is a significant burden to society, and extensive cross-disciplinary research efforts in the fields of science, biology, medicine and engineering are needed to discover effective and novel strategies that provide protective, preventative and therapeutic benefits to both civilians and military personnel as well as improve their quality of life.

1.1. The TBI Research Agenda {#sec1.1}
----------------------------

The ultimate goal of TBI research is to prevent, diagnose and treat TBI in both civilians and military personnel. Several important aspects need to be understood, including the mechanism by which primary injury initiates secondary injury and the sensitivity/specificity of different biomarkers to injury severity. In addition, identifying and evaluating novel targets for pharmacological protection and developing reliable extrapolation methods to predict pharmacological responses in humans are necessary. Toward that objective, U.S. research agencies have initiated several workshops and have funded research groups to understand primary and secondary injury mechanisms, to develop injury criteria and to identify and evaluate targets for pharmacological protection \[[@r74]-[@r77]\]. For example, the U.S. Department of Defense funds numerous TBI-related research projects (to the tune of tens of millions of dollars) that aim to prevent, protect against, diagnose and treat TBI and to improve the quality of life and psychological health of soldiers \[[@r3], [@r78]\]. Despite advances in research and development, healthcare costs associated with TBI are skyrocketing by billions of dollars \[[@r2], [@r4]\]; thus, identifying novel pharmacological strategies that effectively restrain and manipulate the evolution of injury pathways are a primary research focus to address the immediate need for better TBI treatments. We believe that computational models of neuro-axonal injury combined with complementary *in vitro* experiments can help to achieve TBI research objectives in the following ways: a) helping in the interpretation of experimental data, b) aiding in achieving a detailed understanding of injury mechanisms, c) determining mechanical injury thresholds, d) identifying targets for treatments, e) bridging *in vitro* and *in vivo* results, f) enabling animal-to-human scaling and g) aiding the development of optimized treatment strategies.

Given these goals, this article presents the relevance and merits of combination therapies (COMTs) for multi-target manipulation of complex secondary brain injury mechanisms by administering multiple drugs to achieve an optimal therapeutic window of opportunity (*e.g*., temporally broad window) and compares these merits with those of monotherapies (MONTs), which manipulate a single target with a single drug at a time. In the context of the COMTs described in the current article, the drugs are not physically combined; instead, they are administered separately to manipulate the desired targets (*i.e*., injury mechanisms) of the time-dependent secondary TBI cascade. Furthermore, to capture the vast differences in the mechanobiological space and time scales involved, we describe the need for a multiscale TBI model that combines primary biomechanics, secondary injury mechanobiology/neurobiology, pharmacology and mathematical programming techniques to help rationalize combination pharmacotherapy protocols and improve treatment outcomes.

1.2. Outline {#sec1.2}
------------

The paper is organized as follows: Section two briefly reviews the different experimental models of neurotrauma that have been developed to study how primary injury triggers secondary mechanisms. Injury biomarkers, targets and drugs used for pharmacological manipulation (*i.e*., in MONTs) as well as the challenges inherent in TBI treatment are discussed here. The section transitions to a discussion of how COMTs utilize \'multi-target manipulation\' of heterogeneous secondary injury mechanisms to mitigate TBI-induced damage. Section three describes the inherent challenges associated with combination pharmacotherapy and provides a basis for the rational design of optimal protocols to improve treatment outcomes. Section four presents the intellectual merits of model-guided design and optimization of combination pharmacotherapy for brain injury. The paper then closes with a brief overview of the current status, challenges and outlook regarding the use of modeling in future research and development efforts in this area.

**2. Analysis of Secondary Brain Injury** Mechanisms Toward Rational Pharmacolo-**gical Manipulation of Injury Targets**
========================================================================================================================

Many research groups have pursued different approaches to model the effects of primary blast injury on the brain. These studies have aimed to understand how blast waves propagate through the different layers of tissue in the head and to determine the relationship between the intracranial dynamics and primary blast loads. For example, consider breacher studies, which are a type of human blast study involving a unique population among military and law enforcement personnel, known as "breachers", who are repeatedly exposed to low-level blasts (which are considered "safe") during training exercises and operations. The results of these studies have helped to identify not only the consequences of repeated blast injuries and related biomarkers but also the impact of blast exposures on neurocognitive performance \[[@r79], [@r80]\]. Human head surrogates, such as post-mortem human specimens, have also been used to study the effect of blast overpressure on intracranial responses \[[@r81]\]. Additionally, computational modeling groups have developed anatomically consistent head injury models that account for the blast-wave propagation through the tissue layers and vascular spaces of the head to predict the spatiotemporal distribution of stresses and intracranial pressures resulting from different blast overpressures \[[@r8], [@r82]-[@r84]\]. Although the data from these investigations have provided valuable insights into the biomechanical aspects of blast-wave propagation through different head layers and biological interfaces, the precise relationship between the primary and secondary injury is not straightforward (*e.g*., specificity of secondary injury mechanisms to primary blast loads). Thus, to systematically investigate TBI-induced effects, the etiology of secondary injury mechanisms, and the safety and efficacy of new compounds; to identify targets amenable for pharmacological manipulation; and to design optimal pharmacotherapy protocols and methods for human extrapolation, preclinical models of brain injury using well-defined protocols and procedures are often employed as a starting point. An overview of the preclinical models (both animal and *in vitro*) used to elucidate the primary and secondary brain injury mechanisms for the development of pharmacotherapies is provided below.

2.1. Preclinical Models of Brain Injury: Insights into Neuroprotective Mechanisms and Targets {#sec2.1}
---------------------------------------------------------------------------------------------

In animal models of TBI, rodents are typically used as biological specimens to characterize experimental neurotrauma because of their small size, modest cost and ease of manipulation for experiments. Several excellent reviews of the different animal models of TBI (both blunt and blast-induced) have been previously reported \[[@r85]-[@r90]\]. These animal models have provided valuable insight into the pathophysiology of secondary injury and the extracellular and intracellular mechanisms that are involved as well as relevant biomarkers, as illustrated in [Fig. (**[1](#F1){ref-type="fig"}**)](#F1){ref-type="fig"} and briefly described below. Some of the critical mechanisms involve impairments to the following processes: neurophysiological processes, which result in elevated intracranial pressure; metabolic processes, which result in regional hypoperfusion (*i.e*., due to reduced cerebral blood flow) and impaired neurovascular coupling and tissue metabolism; abnormal neurotransmission, which results in excessive neurotransmitter spillover, unintended transport and excitotoxicity in the extracellular space; microglial activation; and mitochondrial processes, which result in oxidative stress, nitrosative stress and apoptosis \[[@r51], [@r91]-[@r94]\]. For example, Giza and Hovda investigated the neurochemical and metabolic cascades following brain injury and found that the onset of cerebral pathophysiology was characterized by an increase in the glycolytic rate \[[@r95]-[@r97]\]. Margulies *et al*. also provided an excellent overview of the different injury mechanisms occurring 72 hours after injury in rodent brain injury models \[[@r50]\]. Additionally, experimental models have helped to identify the increased presence and altered dynamics of autophagy after brain injury, although its mechanistic role in potentiating neuronal cell death and cross-talk with other secondary injury mechanisms is not readily apparent \[[@r98]-[@r102]\].

In addition to animal models, *in vitro* experiments have provided unique insights into the mechanobiological and intracellular aspects of neuro-axonal injury after a mechanical or blast-induced insult. A detailed description of the different *in vitro* approaches to neurotrauma is provided elsewhere \[[@r103]-[@r106]\]. Although the complexity of the *in vivo* brain environment cannot be replicated *in vitro*, elucidating injury mechanisms *in vitro* serves as a useful basis for identifying therapeutic targets and developing treatments. For example, *in vitro* models of neurotrauma using mechanical cell stretching or simulated blast protocols have provided valuable information on the electrophysiological and metabolic consequences of secondary injury that include membrane trauma-induced left shift of the voltage dependence of sodium channels \[[@r107], [@r108]\]; impairments to axonal microtubule-tau structures, transport processes, formation, axonal bulbs and varicosities \[[@r34]-[@r37], [@r109]\]; and impairments to cellular energy metabolism, mitochondrial energetics, calcium signaling, and apoptosis \[[@r110]-[@r112]\]. Furthermore, cell stretching experiments have identified the phenomenon of 'molecular cross-talk', in which injury mechanisms such as oxidative stress, nitrosative stress and caspase-mediated apoptosis compete to induce cell death. Of particular interest is the role of peroxynitrite, which acts as an effective switch between apoptotic and oxidant-mediated cell death by inhibiting caspase-3-mediated apoptosis *via* cysteine oxidation after neurotrauma \[[@r113]\]. Additionally, *in vitro* experiments have revealed that integrin pathways contribute to morphological and cellular changes associated with TBI \[[@r114], [@r115]\]. Injury-induced mechanical perturbations to the neuronal membrane can affect integrin transduction mechanisms and cause abnormal activation of Rho-associated protein kinase (ROCK) signaling pathways; the resulting dysregulation of ROCK activity can trigger the pathogenesis of several neurological disorders \[[@r116]\]. Likewise, complementary *in silico* models of experimental neurotrauma have shed light into how blast-induced stretching and shearing of the neuronal synapses (known as synaptic injury) may cause a provisional disconnect of the neural circuitry and a transient loss in neuronal communication \[[@r117]\].

In addition to identifying the pathways involved in the injury, preclinical models have helped to identify biomarkers of brain injury and pharmacological targets for mitigating the effects of TBI. These biomarkers are usually components of the aforementioned secondary injury pathways and comprise proteins and fragments of cell signaling pathways, endogenously synthesized substances and physiological, biomechanical and electrophysiological quantities (variables/parameters) at different levels of the organism (*i.e*., from cell-level biology to organ-level physiology). Therefore, the relevant biomarkers objectively reflect the physiological state of the organism (*i.e*., healthy or diseased), and their concentrations are thought to vary when an underlying pathology initiates and develops over time (*e.g*., progressive neurological disorders). Therefore, a qualitative and quantitative understanding of biomarker dynamics in both healthy and injured states is an important step toward developing rational treatment protocols, elucidating dose-response relationships and improving outcomes. Biomarkers often serve as primary endpoints in basic and clinical research to predict outcomes and assess the safety and efficacy of drug compounds during the development of new therapies \[[@r118]-[@r121]\]. Accordingly, the identification of disease-specific biomarkers has become a primary focus of many research groups. An excellent review of brain injury biomarkers is discussed elsewhere \[[@r31], [@r122]-[@r130]\]. Although significant progress has been made in the context of injury pathways and biomarkers, determining the specificity and sensitivity of these biomarkers for assessing TBI severity (from primary blast or direct impact) and implementing these biomarkers as clinical diagnostic tools on a large scale remain challenging \[[@r131]\].

A comprehensive review of compounds known to exert neuroprotective effects after brain injury and their corresponding mechanisms of action are discussed in the literature. At least 80 different categories of neuroprotective agents have been tested in preclinical and clinical trials with varying degrees of success; Table **[1](#T1){ref-type="table"}** lists a few of them \[[@r3], [@r5], [@r76], [@r132]-[@r138]\]. These agents include ion channel blockers; calcium antagonists; mitochondrial protective agents; nanoparticles; glutamate transport promoters; NMDA (N-methyl-D-aspartic acid) antagonists (*i.e*., blocking the glycine and polyamine sites); NMDA receptor antagonists (competitive or non-competitive); AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonists; non-NMDA excitatory amino acid antagonists; cholinergic agents; endogenous gasotransmitters and neuromodulators (*e.g*., nitric oxide \[NO\], hydrogen \[H~2~\] and hydrogen sulfide \[H~2~S\]); apoptosis inhibitors; acetylcholinesterase inhibitors; nootropics; phosphodiesterase inhibitors; immunosuppressants; antioxidants, antibiotics; growth factors; statins; neuropeptides; hormones; glutamatergic agents; ROCK inhibitors; anti-inflammatory agents; corticotrophin; immune modulators; and nutraceuticals. Recently, the use of nucleic acid therapeutics to downregulate the undruggable targets within the TBI cascade has been explored *in vitro* \[[@r139]\]. Furthermore, non-pharmacological methods such as hypothermia induction have also been explored to treat brain injury \[[@r140], [@r141]\]; the hypothesis underlying this approach is that mild-to-moderate hypothermia may hinder the TBI-initiated metabolic processes that exacerbate the effects of injury. A detailed discussion of the different aspects and effects of hypothermia therapy is beyond the scope of this article.

2.2. Why Have Current Therapies Failed Despite Increasing Knowledge of the Injury Mechanisms? {#sec2.2}
---------------------------------------------------------------------------------------------

Although a myriad of experimental investigations has shed light on the pathophysiology of brain injury mechanisms and associated comorbidities, little is known regarding how macroscopic biomechanical forces cause cellular injury \[[@r5], [@r19], [@r142], [@r143]\]. Furthermore, the precise path of secondary injury progression, *i.e*., the trajectory of injury and its dynamic progression in the human brain, remains unknown. This non-deterministic nature of the injury trajectory limits the design of rational TBI pharmacotherapies; consequently, clinical trials have failed to demonstrate the efficacy of treatments. This lack of success is likely attributed to several factors, including the complexity and heterogeneity of TBI pathophysiology; the choice of drugs, dosages, delivery routes, dosing regimens, and/or treatment durations; and an incomplete understanding of the pharmacokinetics (PK), dose-response relationships and therapeutic windows \[[@r135], [@r143]\]. Therefore, there is currently no 'magic bullet' for delaying the progression of secondary injury.

To overcome the abovementioned challenges, novel therapies that target multiple components of the secondary injury cascade need to be developed. Thus, instead of relying on a single drug and target at a time, the administration of multiple drugs may result in the multi-target manipulation as illustrated in [Fig. (**[2](#F2){ref-type="fig"}**)](#F2){ref-type="fig"}. Such therapies in which multiple drugs are administered to achieve the desired pharmacodynamic (PD) response by broadening the therapeutic window of opportunity are known as COMTs or 'polytherapies'. COMTs have shown promise in treating conditions such as tuberculosis, cancer, hypertension, rheumatoid arthritis, chronic hepatitis and blood pressure \[[@r144]-[@r147]\]. In COMTs, the actions of multiple drugs may lead to synergistic, additive, or antagonistic responses or, in certain cases, no effect. Antagonistic outcomes are not desirable for drug combinations, and synergistic outcomes may be more desirable than additive outcomes \[[@r3]\]. Regarding the toxicity and efficacy of COMTs, the criteria that these therapies should meet as suggested by Krainer include the following: (a) "each component should have single-agent activity with no cross-resistance", (b) "there should be preclinical evidence of synergistic action" and (c) "the components should have non-overlapping safety profiles" \[[@r148]\].

3. COMT for Multi-Target Manipulation of Secondary Brain Injury Mechanisms {#sec3}
==========================================================================

The starting point for the rational design of COMT protocols is the identification of MONTs that have demonstrated efficacy both *in vitro* and in animal models of TBI (*e.g*., the compounds listed in Table **[1](#T1){ref-type="table"}**). Table **[2](#T2){ref-type="table"}** provides a list of COMTs that have been explored to treat preclinical models of brain injuries. Although preclinical MONTs have provided preliminary insights into specific drug combinations

and their dosages and neuroprotective effects, COMT experiments using MONT drugs can lead to different outcomes. For example, combined pre-injury creatine and post-injury choline administration did not improve the treatment outcomes compared to creatine and choline monotherapies \[[@r143]\]. In a preclinical COMT experiment evaluating the neuroprotective efficacy of the combination of progesterone and vitamin D against ischemic injury, Atif *et al*. showed that the concentration of vitamin D necessary to maximize the efficacy in COMT was different than that tested in MONT; the vitamin D concentration required to achieve a therapeutic effect in the COMT experiment was lower than that in the MONT experiment \[[@r149]\]. Furthermore, a recent article by Margulies *et al*. mentioned that among the six National Institutes of Health (NIH)-sponsored studies testing the efficacy of COMTs in preclinical TBI models, only one study demonstrated significant improvements in long-term behavioral outcomes \[[@r143]\]. We posit that an *in silico* modeling platform can help determine these uncertainties objectively *a priori* and help design pharmacotherapy protocols to maximize treatment outcomes in experimental trials.

The following subsections highlight the inherent challenges in (a) quantifying brain injury mechanisms *via* injury metrics, (b) designing optimal combination pharmacotherapies for brain injury and (c) extrapolating the MONT outcomes from specific preclinical TBI models to either preclinical COMTs or clinical MONTs.

3.1. Experimental Quantification of Brain Injury and Correlation with Human Injury {#sec3.1}
----------------------------------------------------------------------------------

Preclinical TBI models have aided in enhancing our understanding of the effects of external forces on internal stress fields and assessing the safety and efficacy of neuroprotective compounds (partly discussed in Section Two). However, the applicability of animal experimental results to human predictions is not straightforward because of the inherent physiological differences between animals and humans and their dissimilar anthropometric and anatomical characteristics. The use of animal-to-human scaling laws that aim to translate the biomechanical quantities (variables/parameters) in conjunction with *in silico* brain injury models are reported elsewhere \[[@r87], [@r150]\]. Going forward, we anticipate that the development of new formulations will correlate primary injury quantities (variables/parameters) with secondary injury pathways, drug dosage and the desired pharmacodynamic response as well as provide strategies for *in vitro* to *in vivo* correlation.

3.2. Design Challenges Associated with Combination Pharmacotherapy {#sec3.2}
------------------------------------------------------------------

### 3.2.1. Knowledge of the PK and PD of COMTs {#sec3.2.1}

Although the concept of COMTs seems logical and promising, addressing the different design aspects that contribute to the pharmacokinetic outcomes of COMTs is a challenging endeavor. For example, the administration route (*i.e*., the delivery route), the drug delivery sequence, the 'administration scenario' (*i.e*., prophylaxis or treatment), the number of targets to manipulate, and the pharmacokinetic and pharmacodynamic outcomes of the combined administration should be considered, illustrated in Fig. (**[3A](#F3){ref-type="fig"}**-**[C](#F3){ref-type="fig"}**). Furthermore, the pharmacotherapy and resultant outcomes of a drug used in MONT when used in conjunction with another drug are not obvious (*i.e*., PK, PD and toxicodynamics \[TD\]). Thus, a rational choice of the pharmacotherapy variables should rely on the intended targets and the expected PK of the drug such that the drug can elicit the desired PD response when present at the anatomical target at a therapeutic concentration. Regarding sequencing, drugs can be administered (*i.e*., delivered) either concurrently (*i.e*., at the same time *t~1~*) *via* drug-specific delivery routes (*i.e*., intravenous infusion or oral) or sequentially (*i.e*., at different time points, such as *t~1~*, *t~2~*, and *t~3~*). For example, concurrent drug administration may be adopted to effectively target mechanisms that are proximal to each other on the temporal axis, which is conceptually illustrated in Fig. (**[3B](#F3){ref-type="fig"}**) (*e.g*., injury mechanisms in time windows Δ*t~1~* and Δ*t~2~*), whereas delayed administration can be utilized to manipulate mechanisms across different temporal intervals that are not proximal to each other, which is conceptually illustrated in Fig. (**[3C](#F3){ref-type="fig"}**) (*e.g*., injury mechanisms in time windows, Δ*t~1~* and Δ*t~3~*). In COMTs, when multiple drugs target a specific injury mechanism (*e.g*., apoptosis in Fig. **[3B](#F3){ref-type="fig"}** & **[C](#F3){ref-type="fig"}**), it is conceivable that the progression of that mechanism is effectively restrained. Therefore, the therapeutic window of opportunity (also termed as 'overall coverage', Δ*t*) of a combination pharmacotherapy protocol (*i.e*., the number of secondary injury time windows that a COMT protocol can target) will rely on the proper selection of drug candidates, administration routes (*i.e*., delivery routes), drug sequencing and administration scenarios.

### 3.2.2. Information on the TD of COMTs {#sec3.2.2}

Another challenge is the potential for drug-drug interactions (DDIs) and the possible toxicity of the candidate drug combinations in an *in vivo* environment. Although DDIs of certain combinations (*e.g*., those between progesterone and other drugs) may not be clinically significant, the same may not hold true for other combinations, such as combinations of anticonvulsants and barbiturates, which can lead to adverse outcomes \[[@r151]\]. Furthermore, empirically designed COMT experiments could result in inexplicable pharmacokinetic and toxicity profiles that can convolute the extrapolation protocols.

3.3. Adaptation of Preclinical MONT for Preclinical COMT {#sec3.3}
--------------------------------------------------------

### 3.3.1. Rigorous and Comprehensive Investigation of MONT {#sec3.3.1}

In preclinical studies, the safety and efficacy of MONTs must be evaluated for different injury severities (mild, moderate and severe) and in different species (rats, pigs and possibly primates) as well as account for population heterogeneity (*e.g*., the proportions of females and males). Reproducible, high-quality data from such experiments are required for reliable animal-to-human extrapolation \[[@r143]\].

### 3.3.2. Rationale for Assessing Treatment Outcomes for COMT {#sec3.3.2}

In addition to commonly used primary and secondary outcomes such as the Glasgow Outcome Scale, the disability rating scale, and the functional independence measure, the wealth of information on TBI biomarkers must be used to further define primary and secondary outcomes and to provide useful insights into the design of clinical trials \[[@r152], [@r153]\]. Furthermore, preclinical studies must consider neuropsychological outcome measures to evaluate the efficacy of COMTs and to assess the differences between MONTs and COMTs. Excellent discussions of the use of TBI outcome measures have been previously reported in the literature \[[@r154], [@r155]\].

### 3.3.3. Extrapolation of Preclinical MONTs to Design Clinical MONTs {#sec3.3.3}

Although MONTs have shown beneficial results in preclinical models (see Table **[1](#T1){ref-type="table"}**), it is unclear whether the experimental outcomes can be scaled to reliably predict human responses. Some drugs that have worked well in animal models have performed poorly in human TBI trials. These discrepancies or failures to attain clinical success could be attributed to the inherent differences in organ physiology and cellular biology between animals and humans \[[@r156], [@r157]\] and the imprecise application of animal dose-response relationships for assessing safety and efficacy in humans during extrapolation. Specific examples of clinical therapeutic failures (*i.e*., with no clinical benefits or different clinical outcomes) are listed below:

-   Example 1: Consider the clinical performance of progesterone---although progesterone exerted pleiotropic effects and was associated with improved outcomes in preclinical animal TBI models \[[@r3], [@r158]-[@r162]\], the therapeutic potential of progesterone was not observed in multicenter Phase III clinical trials, such as the NIH-funded ProTECT trial (Progesterone for the Treatment of Traumatic Brain Injury III, ClinicalTrials.gov number NCT00822900) \[[@r163], [@r164]\] and the BHR Pharma-funded SYNAPSE trial (Study of the Neuroprotective Activity of Progesterone in Severe Traumatic Brain Injuries, ClinicalTrials.gov number NCT01143064) \[[@r152]\]. It has been postulated that the clinical failure of progesterone was due to the intrinsic complexity of TBI mechanisms acting in parallel, a lack of preclinical data from different animal models (rodents, higher animals and possibly primates) and reliable biomarkers and the absence of reliable multi-dimensional TBI characterization methods beyond the commonly used TBI measures \[[@r142], [@r152]\].

-   Example 2: Consider the efficacy of citicoline as a TBI treatment in Phase III clinical study called CORBIT (Citicoline Brain Injury Treatment Trial, ClinicalTrials.gov number NCT00545662): ninety days of citicoline administration did not improve the functional or cognitive states of TBI patients \[[@r165], [@r166]\].

-   Example 3: Although the combined estrogen/progestin formulation Prempro exhibited neuroprotective effects in animal models, no positive effects were observed in clinical trials; instead, Prempro increased the risk of dementia and stroke \[[@r167]-[@r169]\].

Considering the abovementioned challenges, a systematic approach to rationally design combination pharmacotherapy protocols is a necessary first step to improve treatment outcomes as well as facilitate and accelerate clinical testing. We posit that multiscale computational algorithms that integrate whole-body physiology/biology, drug pharmacology (*i.e*., PK, PD, and TD), primary and secondary injury mechanisms, and embedded mathematical programming techniques (optimization) can help accelerate the development of personalized therapies and improve treatment outcomes. To this end, the next section briefly presents the current status, challenges and outlook for future research and development in this area.

4. Modeling of Brain Injury Mechanisms: Current Status and Recommendations for Model-Guided Pharmacotherapy {#sec4}
===========================================================================================================

Computational modeling of the different aspects of TBI has matured over the last few decades. Regarding primary injury biomechanics, several groups have developed analytical, spring-mass-damper and computational fluid dynamics (CFD) models to describe macroscopic brain biomechanics, accidental impacts and vehicle crashes \[[@r82]-[@r84], [@r170]-[@r175]\]. In particular, advanced three-dimensional CFD finite-element models of the cranial anatomy have gained popularity for simulating impact and blast biomechanics \[[@r8], [@r176], [@r177]\]. With steady refinements, these models have provided insight into how brain injury perturbs the distribution of stress/strain fields and intracranial pressure within the brain parenchyma. Furthermore, these models are being adapted to rationalize the design of protective equipment such as helmets. However, we suggest that the scope of the existing models of primary injury biomechanics can be further augmented by accounting for anatomically and physiologically consistent features (*e.g*., the elasticity of the skull, the flexibility of the neck and head, and the presence of cerebrospinal fluid), multiscale coupling of macroscale body/brain scale biomechanics with microscale mechanobiology to quantify the effects of primary micro-damage to neuro-axonal structures as well as by improving solvers to accommodate the spatiotemporal scales.

Regarding progress in neuronal electrophysiology, a myriad of *in vitro* and *in vivo* investigations from several experimental and modeling groups have shed light on the electrophysiological and biological aspects of both single neuron activity and large neuronal networks and have also provided neurobiological data supporting the development and validation of mathematical models \[[@r178]-[@r184]\]. While the outcomes have resulted in the development of simulators such as NEURON, GENESIS, MOOSE and LfPy \[[@r185]-[@r191]\], little progress has been made in modeling the microscale mechanobiology, electrophysiology and systems biology of damaged neuro-axonal structures. Regarding the secondary injury mechanisms, although individual models of the different injury pathways have been developed, a combined model linking the temporally distributed mechanisms has not been developed \[[@r192]-[@r198]\] partially because of a lack of precise information on the secondary injury trajectory in response to primary injury loads. Additionally, model-guided pharmacological manipulation of these pathways (supported by experimental data) has not been fully explored. Furthermore, the merits of using mathematical programming techniques for designing optimal pharmacotherapy protocols to achieve these outcomes have not yet been evaluated.

Going forward, we envision an integrated multiscale computational model of TBI that combines models of primary injury biomechanics, blood flow, cerebral hemodynamics, cerebrospinal fluid dynamics, secondary injury mechanisms, physiological and mechanobiological/neurobiological processes, and pharmacology (*i.e*., PK/PD/TD responses); a schematic of this integration is shown in [Fig. (**[4](#F4){ref-type="fig"}**)](#F4){ref-type="fig"}. Once an effective multiscale computational model of brain injury pharmacology has been developed and validated with complementary experimental data, the integrated model will enable researchers to address the ultimate goals TBI research (as discussed in Section two), which are summarized below:

-   understand how primary injury initiates the pathogenesis of secondary injury mechanisms

-   shed light on the injury trajectory, injury pathways and drug targets

-   provide a platform for conducting virtual experiments to explore the safety and efficacy of novel prophylactic and neurotherapeutic strategies in manipulating injury pathways and to facilitate the development of drug candidates

-   re-evaluate the clinical efficacy of drugs that have shown promise in preclinical trials but have failed in subsequent clinical trials

-   conduct dose-response studies to design reproducible experiments with scalable outcomes

-   extrapolate *in vitro* and animal data to predict human-relevant responses

Preclinical data from novel *in vitro* platforms such as human-on-chip platforms, which aim to integrate multiple organs on a chip to emulate the human responses to drugs, can also be explored to investigate the pharmacokinetic properties and PK/PD/TD responses of novel neurotherapeutics as well as potential synergistic effects when delivered in conjunction with other drugs \[[@r199]-[@r202]\]. In an ongoing U.S. Defense Advanced Research Projects Agency (DARPA)-funded project, computational approaches are being developed to rationalize the use of *in vitro* organ-on-chip technology to extrapolate on-chip data, with the goals of predicting human responses, accelerating drug testing \[[@r203], [@r204]\], and anticipating human responses using *in vitro* to *in vivo* extrapolation methods \[[@r205]\].

Regarding combination pharmacotherapies, the multiscale TBI model will seek to accomplish the following:

-   to help adapt preclinical MONT candidates for COMTs and to identify the optimal drug administration sequence to achieve a temporally broad therapeutic window of opportunity

-   to predict the PK, PD and TD of COMTs and to identify the synergistic, additive and antagonistic effects

-   to identify the design challenges associated with COMTs and to engineer methods to devise optimal pharmacotherapy protocols

-   to extrapolate preclinical COMT protocols to predict human-relevant responses

4.1. Example of Model-guided Optimization of COMT Protocols {#sec4.1}
-----------------------------------------------------------

Mathematically, the design of optimal COMT protocols can be considered a constrained optimization problem in which the objective is to effectively target multiple secondary injury mechanisms with drug safety and efficacy as regulatory constraints *i.e.,* the combined therapy must be efficacious and should not cause toxicity due to potential DDIs, undesirable PK or anomalous drug behavior at either the anatomical target or other peripheral regions. Table **[3](#T3){ref-type="table"}** mathematically illustrates the constraints and optimization parameters necessary to achieve the proposed objective. A mathematical description of such optimization methods is discussed elsewhere \[[@r206]\].

To the best of our knowledge, a multiscale data-driven computational model for predicting the extent of TBI-induced brain damage and identifying the pharmacological avenues for mitigating brain damage within a unified multiscale framework has not yet been reported in the published literature. In the near future, we envision that a model-guided approach will help to improve the development and performance of protective, preventative and treatment strategies. Model-guided COMTs can help to rationalize combination pharmacotherapy protocols by identifying the optimal candidates for COMTs and their ideal delivery sequences and doses to effectively contain and mitigate the progression of secondary injury mechanisms and improve treatment outcomes. Furthermore, a rigorously validated multiscale TBI model can help predict the safety and efficacy of new therapeutic compounds for experimental investigations *a priori*. In the long-term, the model-guided approach has the potential to revolutionize the management and treatment of head injuries resulting from sports, motor vehicle accidents and combat missions.

M.R.S. and A.J.P. acknowledge financial support from the U.S. Department of Defense Congressionally Directed Medical Research Programs (CDMRP) under contract W81XWH-11-2-0057 for this work. MRS and AJP would also like to thank Prof. Irshad Chaudry, PhD, and Dr. William Hubbard, PhD, at the University of Alabama at Birmingham for sharing their scientific insights on neuropharmacology from a related project.

Akt

:   Protein kinase B (PKB)

AMPA

:   α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid

CFD

:   Computational fluid dynamics

CORBIT

:   Citicoline Brain Injury Treatment Trial

COMT

:   Combination therapy or therapies

CREB

:   cAMP response element binding protein, a cellular transcription factor

DAI

:   Diffuse axonal injury

DARPA

:   U.S. Defense Advanced Projects Research Agency

DDIs

:   Drug-drug interactions

E2

:   17β Estradiol

eNOS

:   endothelial nitic oxide synthase

ERK

:   Extracellular signal-regulated kinase

GCS

:   Glasgow Coma Scale

GENESIS

:   General Neural Simulation System

IGF

:   Insulin-like growth factor

iNOS

:   Inducible nitic oxide synthase

MAPK

:   Mitogen-activated protein kinase

MOOSE

:   Multiscale Object-Oriented Simulation Environment

MPS

:   Maximum principal strain

MONT

:   Monotherapy or monotherapies

NMDA

:   N-methyl-D-aspartic acid or N-methyl-D-aspartate

NF-κB

:   Nuclear factor κ-light-chain-enhancer of activated B cells

NO

:   Nitric oxide

PEG-SOD

:   Superoxide dismutase-polyethylene glycol

PI3K

:   Phosphatidylinositol-4,5-bisphosphate 3-kinase

PK

:   Pharmacokinetics

PD

:   Pharmacodynamics

ProTECT

:   Progesterone for the Treatment of Traumatic Brain Injury III

TBI

:   Traumatic brain injury

TD

:   Toxicodynamics

TLR

:   Toll-like receptor

ROCK

:   Rho-associated protein kinase

SOD

:   Superoxide dismutase

SYNAPSE

:   Study of the Neuroprotective Activity of Progesterone in Severe Traumatic Brain Injuries
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![Pathogenesis of secondary brain injury mechanisms in response to primary injury (*e.g*., primary blast-induced or direct impact). This schematic illustrates the injury progression from primary (macroscale biomechanics) to post-primary injury (microscale mechanobiology) and culminates at the onset of time-dependent secondary injury mechanisms (biological); these pathways are largely based on preclinical models. The long duration and complexity of secondary injury provide opportunities for rational interventions, pharmacological or psychological protection, and treatment of the brain injury.](CN-16-484_F1){#F1}

![Conceptual diagram of multi-target manipulation of the dynamically evolving secondary injury cascade using combination therapy as illustrated on the temporal axis (*t~1~-t~5~*). Different drugs (*e.g*., D~1~-D~5~) act on their respective targets, *i.e*., on the specific injury mechanism, within the time windows (Δ*t~1~-~5~*). The combined drug actions aim to broaden the therapeutic window of opportunity to achieve better treatment outcomes.](CN-16-484_F2){#F2}

![TBI combination pharmacotherapy and multi-target manipulation of secondary injury pathways. (A) Combinations of drug administration routes (*i.e*., delivery routes such as intravenous bolus, intravenous infusion and oral) and (B-C) conceptual illustrations of expected pharmacological responses based on the drug sequencing (concurrent or delayed). In the context of the COMT described here, the drugs are not physically combined; instead, they are separately administered to effectively manipulate the desired targets (*i.e*., injury mechanisms) in the time-dependent secondary TBI cascade. In concurrent administration, the drugs are administered (*i.e*., delivered) at the same time point *t~1~*, whereas in delayed administration, the drugs are administered at different times (*i.e*., *t~1~*, *t~2~*, and *t~3~*). The pharmacokinetic profiles, *C(t)*, the drug bioavailability, the pharmacodynamic responses in the brain and the therapeutic window of opportunity (*i.e*., the number of secondary injury time windows, Δ*t*, that can be targeted by a combination pharmacotherapy protocol, termed 'overall coverage' here) will rely on the proper selection of drug candidates, administration routes, drug sequencing and 'administration scenarios' (*i.e*., prophylaxis or treatment, not to be confused with administration routes). Model-guided simulations can help identify the optimal drugs and their sequence and can help design pharmacotherapy protocols to achieve the desired outcomes (*i.e*., safety and efficacy) by optimizing these therapeutic variables.](CN-16-484_F3){#F3}

![An integrated multiscale TBI model linking the model components across different spatial and temporal scales for the rational design and optimization of pharmacotherapies (*i.e*., MONTs and COMTs), drug evaluation and research. This article identifies the need to develop such models in the near future and supports the notion that model-guided approaches can help to accelerate drug development and rationalize treatment protocols to improve treatment outcomes.](CN-16-484_F4){#F4}

###### 

Selected list of neurotherapeutics that have been evaluated for the treatment of brain injury in preclinical and clinical trials.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Drug Category (Neurotherapeutic)**                                             **Mechanism of Action/Outcome(s)**
  -------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Hormone therapy\                                                                 • exerts neuroprotective effects *via* genomic mechanisms (delayed onset and prolonged duration *via* nuclear estrogen receptors) and non-genomic mechanisms (rapid onset and short duration *via* estrogen receptors in the plasma membrane resulting in the activation of signaling cascades such as kinase pathways---ERK/MAPK and PI3K/Akt, CREB, etc.) \[[@r207]-[@r209]\]; exerts neurotrophic effects \[[@r210]\]\
  (17β estradiol, E2)                                                              • regulates ion channels, second messengers, and kinase signaling pathways and reduces intracellular calcium overload to promote neuronal viability \[[@r207], [@r211]\]\
                                                                                   • promotes energy metabolism and mitochondrial function in metabolically compromised states to exert neuroprotection \[[@r212], [@r213]\]\
                                                                                   • attenuates glutamate-induced calcium overload in primary rat hippocampal neuron cultures \[[@r214]\]\
                                                                                   • attenuates abnormal excitation of neurons following perturbations in cerebral blood flow \[[@r215]\]\
                                                                                   • attenuates glutamate-induced calcium overload in primary rat hippocampal neuron cultures \[[@r214]\] and the accumulation of extracellular excitatory amino acids \[[@r216]\]\
                                                                                   • improves outcomes after cerebral ischemia and promotes cerebral blood flow recovery in experimental models \[[@r217]-[@r219]\]

  Hormone therapy\                                                                 • exerts both genomic and non-genomic effects; increases cerebral perfusion pressure; stabilizes the blood-brain barrier; decreases neuronal degeneration, apoptosis, and reactive astrogliosis; edema and intracranial pressure; increases cerebral glycolysis in a rat TBI model \[[@r220]\]
  (estrogen sulfate, E~2~-SO~4~)                                                   

  Hormone therapy\                                                                 • modulates excitotoxicity \[[@r160]\]\
  (progesterone)                                                                   • downregulates TBI-induced inflammation and cerebral edema \[[@r158], [@r160], [@r162], [@r221]\]; attenuates TBI-induced activation of the TLR/NF-κB signaling pathway to improve outcomes \[[@r222]\]; reconstitutes the blood-brain barrier \[[@r161]\]\
                                                                                   • clinical trials \[[@r153], [@r163], [@r223]\]

  Tetracycline antibiotics\                                                        • exhibit anti-inflammatory and anti-apoptotic properties; reduce TBI-mediated tissue injury and caspase-1 activity; improve spatial memory and neurological outcome after TBI \[[@r224], [@r225]\]
  (*e.g*., minocycline, doxycycline)                                               

  Acetylcholinesterase Inhibitors (*e.g*., donepezil, rivastigmine, galantamine)   • increase synaptic acetylcholine by inhibiting acetylcholinesterase breakdown in the synapse; reduce edema and improve cognitive outcomes \[[@r3], [@r19]\]

  Immunosuppressant Cyclosporin A                                                  • maintains the mitochondrial membrane homeostasis by inhibiting the opening of the mitochondrial permeability transition pore; maintains calcium homeostasis \[[@r3], [@r5], [@r226], [@r227]\]

  Erythropoietin                                                                   • attenuates glutamate toxicity; have anti-apoptotic, antioxidant, and anti-inflammatory effects; increases hematocrit level; stimulates neurogenesis \[[@r3]\]

  ROCK Inhibitors\                                                                 • reduce neuronal focal swelling after neuronal injury *in vitro* \[[@r114]\]; improves neurological functions after ischemia stroke, subarachnoid hemorrhage and other central nervous system disorders, observed in clinical trials \[[@r228]-[@r230]\]
  (*e.g*., fasudil \[HA-1077\])                                                    

  Antioxidants\                                                                    • inhibit free radical-induced oxidative damage and lipid peroxidation and its effects in potentiating cellular injury \[[@r135], [@r136]\]
  (*e.g*., Cu/Zn SOD,\                                                             
  PEG-SOD, tirilazad, dexanabinol)                                                 

  Antioxidant nanoparticles (*e.g*., ceria)                                        • reduces free radical damage, calcium dysregulation and neuronal death *in vitro* and *in vivo* \[[@r231], [@r232]\]\
                                                                                   • preserves the lifespan of mixed organotypic cultures of brain cells and pure neurons, while preserving normal calcium signaling during the extended lifespan \[[@r233], [@r234]\]\
                                                                                   • radical scavenging activity of ceria is regenerative under biological conditions permitting sustained activity \[[@r132], [@r233], [@r235]-[@r237]\]

  Nootropics\                                                                      • known to improve cognitive functions in rat TBI models \[[@r26], [@r132], [@r138]\]
  (*e.g*., BMY-21502, cerebrolysin, pyrrolidine derivatives)                       

  **Drug Category (Neurotherapeutic)**                                             **Mechanism of Action/Outcome(s)**

  Nutraceuticals\                                                                  • nutritional agents/food supplements known to protect the brain \[[@r132], [@r238]\]
  (*e.g*., vitamins, creatine, nicotinamide, resveratrol, curcumin)                

  Gasotransmitters\                                                                • these gases are synthesized endogenously and act as key modulators on intracellular pathways to exert certain regulatory functions such as vasoactivity, signal transmission and neurotransmitter release \[[@r132], [@r239], [@r240]\]; and antioxidant, anti-inflammatory and anti-apoptotic effects \[[@r241]-[@r243]\]. The role of NO seems debatable as it can act as both a signaling molecule and a neurotoxin \[[@r244]\]. In particular, NO derived from endothelial nitric oxide synthase (eNOS) is thought to possess neuroprotective properties whereas NO derived from inducible nitric oxide synthase (iNOS) appears to have neurotoxic properties \[[@r240]\]. Accordingly, iNOS inhibitors have been evaluated for their neuroprotective properties \[[@r245], [@r246]\].
  (*e.g*., NO therapeutics, molecular H~2~, H~2~S)                                 
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Examples of COMTs that have been evaluated in preclinical and clinical trials for the treatment of brain injury.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Combination Therapy**                                                                                                            **Experimental Model \[Observation\]**
  ---------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ^\#^Progesterone (P4) and\                                                                                                         Neuronal cultures (oxygen glucose deprivation model in primary cortical neurons) and the ischemic transient middle cerebral artery occlusion model in rats \[P4 and VDH demonstrated neuroprotection when administered individually; the effective concentration of VDH in COMT was lower than that observed in the MONT; the drug combination modulated neuroinflammation, oxidative damage and growth factors by triggering brain-derived neurotrophic factor (BDNF)/TRK-B/ERK1/2 signaling, resulting in a smaller infarct volume and improved functional recovery\]
  vitamin D hormone (VDH) \[[@r149]\]                                                                                                

  ^\#^Glypromate and minocycline \[[@r143]\]                                                                                         Rat TBI model \[synergistically decreased microglial reactivity and impaired axonal transport and caspase-3 activation\]

  Marrow stromal cells and simvastatin \[[@r247]\]                                                                                   Rat TBI model \[synergistic drug effect improved functional outcomes\]

  Dexamethasone and melatonin \[[@r248]\]                                                                                            Mouse TBI model \[synergistic drug effect reduced edema, oxidative stress, brain infarction and expression of apoptotic proteins\]

  Vitamin D3, progesterone, omega-3 fatty acids and glutamine \[[@r249]\]                                                            Clinical trials \[downregulated cytokine production, prevented oxidative stress (free radical oxygen formation), and reduced cerebral edema and inflammation\]

  ^\#^Probenecid and N-acetyl cysteine (NAC)\                                                                                        Rat TBI model \[probenecid increased the brain penetration/bioavailability and therapeutic potential of NAC\]
  \[[@r133], [@r143], [@r250]\]                                                                                                      

  Minocycline and glutathione precursor\                                                                                             Rat TBI model \[drug combination reduced myelin loss, improved spaced learning, modulated inflammation and attenuated CD68-expressing phagocytic microglia without astrocyte activation at impact site; synergistic drug effect improved executive function and long-term memory\]
  NAC \[[@r251], [@r252]\]                                                                                                           

  Minocycline and botulinum toxin (Botox)-induced limb constraint \[[@r253]\]                                                        Rat TBI model \[synergistic drug effect reduced inflammation and spatial memory impairment\]

  E2 and memantine \[[@r254]\]                                                                                                       Organotypic hippocampal-slice cultures from Sprague-Dawley rats were subjected to TBI *in vitro* \[synergistic drug effect attributed to memantine blocking the deleterious E2-mediated enhancement of NMDA receptors; drug combination significantly reduced cell death\]

  ^\#^Small interfering RNA (siRNA) targeting aquaporin water channel (siAQP4) and c-Jun N-terminal kinase-1 inhibitor (D-JNKI-1)\   Rat TBI model \[the combination of siAQP4 and D-JNKI-1 improved spatial memory in comparison to nontreated juvenile rats two months after injury; improvement plateaued due to statistically indistinguishable outcomes between COMTs and MONTs (*i.e*., siAQP4 or D-JNKI-1 alone) for behavioral outcomes\]
  \[[@r143], [@r255], [@r256]\]                                                                                                      

  ^\#^Creatine and choline \[[@r143]\]                                                                                               Rat TBI model \[drug combination did not lead to additive or synergistic actions; no significant improvements over monotherapies \[[@r257]-[@r260]\]\]

  ^\#^Nicotinamide and progesterone \[[@r261]\]                                                                                      Rat TBI model \[drug combination offered improved neuroprotection and functional recovery in sensorimotor tasks; reduced neuronal degeneration and glial response after injury\]
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\#NIH-sponsored study.

###### 

Illustration of the mathematical optimization of COMT protocols to maximize efficacy without compromising the safety constraints (*i.e*., drug toxicity). Multiscale integrated models of brain injury linked to whole-body PK/PD/TD that are embedded with optimization techniques can accelerate drug development, experimental and regulatory testing, evaluation, and clinical translation.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Objective:** To achieve the desired therapeutic window of opportunity (*e.g*., broad overall coverage) for the effective multi-target manipulation of secondary injury mechanisms\
  **Constraints:** Regulatory constraints, *i.e*., safety and efficacy\
  Safety (*e.g*., toxicity due to drug overload, washout to unintended areas, DDIs in the *in vivo* environment, antagonistic effects)\
  Efficacy (*e.g*., primary and secondary biomarkers of treatment outcomes)\
  **Optimization parameters (*i.e*., the pharmacotherapy design variables/parameters):**\
  What to administer (drug candidates)\
  How to administer (concurrent or delayed, inlet concentration, and other related factors)\
  Delivery route (intravenous bolus or infusion, oral or other)\
  When to administer (treatment or prophylaxis, *i.e*., pre- and/or post-injury administration times, termed as 'administration scenarios')

  **Expected outcome(s):** *In silico* model-guided design of optimal pharmacotherapy protocol(s) can be implemented to effectively manipulate secondary brain injury mechanisms within the safety limits and to gain insights into the systemic pharmacokinetics, bioavailability and action of drug(s) in the brain microenvironment (pharmacodynamics).
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
